Cargando…
Difficulty in Repurposing Selective Serotonin Reuptake Inhibitors and Other Antidepressants with Functional Inhibition of Acid Sphingomyelinase in COVID-19 Infection
The rapid spread of COVID-19 has become a health emergency causing an urgent need for drug treatments to control the outbreak, especially in more vulnerable individuals. This is reinforced by the fact that prophylactic vaccines and neutralizing monoclonal antibodies may not be fully effective agains...
Autores principales: | Le Corre, Pascal, Loas, Gwenolé |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927035/ https://www.ncbi.nlm.nih.gov/pubmed/35308205 http://dx.doi.org/10.3389/fphar.2022.849095 |
Ejemplares similares
-
Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection
por: Loas, Gwenolé, et al.
Publicado: (2021) -
Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study
por: Darquennes, Gil, et al.
Publicado: (2021) -
Selective Serotonin Reuptake Inhibitor Antidepressant Treatment Discontinuation Syndrome: A Review of the Clinical Evidence and the Possible Mechanisms Involved
por: Renoir, Thibault
Publicado: (2013) -
Comparative efficacy and acceptability of selective serotonin reuptake inhibitor antidepressants for binge eating disorder: A network meta-analysis
por: Duan, Hanying, et al.
Publicado: (2022) -
Pediatric Therapeutic Drug Monitoring for Selective Serotonin Reuptake Inhibitors
por: Strawn, Jeffrey R., et al.
Publicado: (2021)